Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression-Reference-Cited by-同舟云学术

Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression

Published:2019-01-02 Issue:10 Volume:39 Page:2267-2274
ISSN:0165-5701
Container-title:International Ophthalmology
language:en
Short-container-title:Int Ophthalmol

Author:

Vural Aslı^ORCID,Ekinci Dilbade Yıldız,Onur Ismail Umut,Hergünsel Gülsüm Oya,Yiğit Fadime Ulviye

Publisher

Springer Science and Business Media LLC

Subject

Ophthalmology

Link

http://link.springer.com/content/pdf/10.1007/s10792-018-01064-7.pdf

Reference29 articles.

1. Stenkuller PG, Du L, Gilbert C, Foster A, Collins ML, Coats DK et al (1999) Childhood blindness. J AAPOS 3:26–32

2. Klufas MA, Chan RV (2015) Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: what we know after 7 years. J Pediatr Ophthalmol Strabismus 52:77–84

3. Wu WC, Lien R, Liao PJ, Wang NK, Chen YP, Chao AN, Chen KJ, Chen TL, Hwang YS, Lai CC (2015) Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. JAMA Ophthalmol 133:391–397

4. Zhou Y, Jiang Y, Bai Y, Wen J, Chen L (2016) Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab. Graefe’s Arch Clin Exp Ophthalmol 254:31–36

5. Pertl L, Steinwender G, Mayer C, Hausberger S, Pöschl EM, Wackernagel W, Wedrich A, El-Shabrawi Y, Haas A (2015) A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity. PLOS ONE 10(6):e0129383

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vascular development analysis: a study for tertiary anti-vascular endothelial growth factor therapy after second reactivation of retinopathy of prematurity;Frontiers in Medicine;2024-07-19

2. Evidence based management of retinopathy of prematurity: More than meets the eye;Clinical Epidemiology and Global Health;2024-03

3. Fluorescein Angiography Evaluation of Children Previously Treated with Anti-VEGF Monotherapy for Retinopathy of Prematurity;Retina;2023-12-26

4. Evaluation of retinal vascularization in retinopathy of prematurity regressed after intravitreal ranibizumab monotherapy or without treatment based on fluorescein angiography;Scientific Reports;2023-11-15

5. Retinopathy of prematurity risk predictors in peripheral avascular retina after intravitreal ranibizumab treatment: Vasculogenesis analysis Running Title: Predictors for Retinopathy Recurrence Post-Ranibizumab;2023-11-03